688767 Hangzhou Biotest Biotech
- 26.54
- -0.34-1.26%
Hangzhou Biotest Biotech News
Express News | Star market review: Ndamu's first day of listing rose by 176.91%, SSE Science and Technology Innovation Board 50 Index fell by 0.12%.
Botuo Biotech (688767.SH) will distribute 8 yuan for every 10 shares in 2023. The stock registration date is June 7
Botuo Biotech (688767.SH) announced that the company will implement the 2023 annual equity distribution to all shares...
Botuo Biotech (688767.SH): Has repurchased a total of 2.109,800 shares of the company's shares
Gelonghui, June 2, 丨 Botuo Biotech (688767.SH) announced that as of May 31, 2024, the company had repurchased 2.109,800 shares of the company's shares through centralized bidding transactions, accounting for 1.9780% of the company's total share capital. The highest price of the repurchase transaction was 33.48 yuan/share, the lowest price was 22.23 yuan/share, and the total amount of capital paid was RMB 569.32 million (excluding transaction fees such as stamp duty and transaction fees).
Botuo Biotech (688767.SH): Currently, POCT industry competition is fierce, and POCT products are under pressure to reduce prices
Gelonghui, May 13 | Botuo Biotech (688767.SH) recently said during a survey reception from institutional investors that currently the POCT industry is fiercely competitive, and POCT products are under certain price reduction pressure.
Botuo Biotech (688767.SH): Will continue to focus on POCT testing tracks
Gelonghui, May 13 | Botuo Biotech (688767.SH) recently said during a survey receiving institutional investors that the company will continue to focus on the POCT testing circuit, give full play to the technology, product, quality and sales advantages that the company has accumulated over the years, and launch new products with higher cost performance, higher sensitivity, and closer to customer usage needs in colloidal gold technology. In terms of new technology platforms, efforts are being made to expand the variety of immunofluorescence products, increase the number of registration certificates for immunofluorescence products, further improve product quality through microfluidic control technology, and create new technology products with differentiated advantages. At the same time, the company is working hard to find the right shape on the outside
Botuo Biotech (688767.SH): COVID-19 related assets have been prepared for depreciation in 2023
Gelonghui, May 13 | Botuo Biotech (688767.SH) recently said during a survey reception from institutional investors that the total asset impairment losses calculated by the company in 2023 were 588.364 million yuan, mainly inventory impairment losses, with a small portion being credit impairment losses. COVID-19 related assets have been prepared for depreciation in 2023 and will not have an impact on subsequent reporting periods.
Botuo Biotech (688767.SH): Domestic sales of influenza A and B testing products achieved rapid growth in 2023. Non-COVID-19 infectious disease series products increased 84.98% year-on-year
Gelonghui, May 13丨Botuo Biotech (688767.SH) recently said during a survey receiving institutional investors that the operating revenue of drug testing and infectious disease testing series products in 2023 accounts for more than 80% of the company's total revenue. Domestic sales of influenza A and B testing products achieved rapid growth in 2023. Non-COVID-19 infectious disease series products increased by 84.98% over the same period last year. The drug abuse (drug) testing series products also achieved a certain increase over the same period last year.
Retail Investors Are Hangzhou Biotest Biotech Co.,Ltd.'s (SHSE:688767) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥404m Last Week
Key Insights The considerable ownership by retail investors in Hangzhou Biotest BiotechLtd indicates that they collectively have a greater say in management and business strategy 55% of the business
Botuo Biotech (688767.SH): Purchased 1.9780% of the company's shares at a total cost of 569.302 million yuan
Gelonghui, April 30, 丨 Botuo Biotech (688767.SH) announced that as of April 30, 2024, the company had repurchased 2.109,800 shares of the company's shares through centralized bidding transactions, accounting for 1.9780% of the company's total share capital of 106,666,667 shares. The highest price of the repurchase transaction was 33.48 yuan/share, the lowest price was 22.23 yuan/share, and the total amount of capital paid was RMB 569.302 million (excluding transaction fees such as stamp duty and transaction fees).
Botuo Biotech (688767.SH): Net profit of 39.63 million yuan in the first quarter increased 233.05% year-on-year
Gelonghui, April 26 | Botuo Biotech (688767.SH) released its first quarter report. Operating revenue was 136 million yuan, up 30.81% year on year, net profit of 39.63 million yuan, up 233.05% year on year, after deducting non-net profit of 394.397 million yuan, up 335.55% year on year, with basic earnings of 0.38 yuan per share.
Botuo Biotech (688767.SH): Purchased 1.8750% of the company's shares at a total cost of 54.273,400 yuan
Gelonghui, April 2, 丨 Botuo Biotech (688767.SH) announced that as of March 31, 2024, the company had repurchased 2 million shares of the company's shares through centralized bidding transactions, accounting for 1.8750% of the company's total share capital of 106,666,667 shares. The highest price of the repurchase transaction was 33.48 yuan/share, the lowest price was 22.23 yuan/share, and the total amount of capital paid was RMB 542,2734 million (excluding transaction fees such as stamp duty and transaction fees).
Botuo Biotech (688767.SH): Purchased a total of 1.7165% of the company's shares at a cost of 49.98 million yuan
Gelonghui, March 1, 丨 Botuo Biotech (688767.SH) announced that as of February 29, 2024, the company had repurchased a total of 1,830,900 shares through the Shanghai Stock Exchange trading system, accounting for 1.7165% of the company's total share capital of 106,666,667 shares. The highest price of the repurchase transaction was 33.48 yuan/share, the lowest price was 22.23 yuan/share, and the total amount of capital paid was RMB 49.98 million (excluding transaction fees such as stamp duty and transaction fees).
Botuo Biotech (688767.SH): Net profit in 2023 fell 85.62% year on year
Gelonghui, Feb. 23: Botuo Biotech (688767.SH) announced its 2023 annual performance report. During the reporting period, the company achieved total revenue of 442.3642 million yuan, down 76.73% from the same period last year; realized net profit attributable to owners of the parent company of 111.265,500 yuan, a decrease of 85.62% over the same period last year; realized net profit attributable to owners of the parent company after deducting non-recurring profit and loss of 84.0849 million yuan, a decrease of 88.88% from the same period last year.
Investor Optimism Abounds Hangzhou Biotest Biotech Co.,Ltd. (SHSE:688767) But Growth Is Lacking
There wouldn't be many who think Hangzhou Biotest Biotech Co.,Ltd.'s (SHSE:688767) price-to-sales (or "P/S") ratio of 5.4x is worth a mention when the median P/S for the Biotechs industry in China is
Botuo Biotech (688767.SH) has spent 34.366,600 yuan to buy back 1.11% of the shares
Zhitong Finance App News, Botuo Biotech (688767.SH) announced that as of January 31, 2024, the company had repurchased 1.18 million shares of the company through centralized bidding transactions through the Shanghai Stock Exchange trading system, accounting for 1.11% of the company's total share capital, an increase of 0.68% compared with the previous disclosure. The highest price of the repurchase transaction was 33.48 yuan/share, the lowest price was 25.63 yuan/share, and the total amount of capital paid was RMB 34,366,600 (excluding transaction fees such as stamp duty and transaction fees).
Biotech (688767.SH): Net profit pre-reduced by 86.30% to 85.01% in 2023
Gelonghui, January 30丨Botuo Biotech (688767.SH) announced its 2023 annual results forecast. According to preliminary estimates by the finance department, net profit attributable to owners of the parent company is expected to be 106 million yuan to 116 million yuan in 2023. Compared with the same period of the previous year (statutory disclosure data), a decrease of 66,765.42 million yuan to 657.6542 million yuan, a year-on-year decrease of 86.30% to 85.01%. Net profit attributable to the owner of the parent company after deducting non-recurring profit and loss is expected to be between RMB 78.7 million and RMB 88.7 million in 2023
Botuo Biotech (688767.SH): The company is still working to expand the product range of fluorescence immunochromatography testing products
Gelonghui, January 3, 丨 Botuo Biology (688767.SH) said when receiving research from specific subjects that the company is still working to expand the product range of fluorescence immunochromatography testing products. Currently, it has obtained more than 30 CE certificates, and several domestic products have entered the registration stage.
Botuo Biotech (688767.SH): The company has a medical device certificate for influenza A/B virus antigen detection reagents in China
Gelonghui, January 3, 丨 Botuo Biotech (688767.SH) said during an investigation with specific subjects that the company has a medical device certificate for influenza A/B virus antigen detection reagents in China, and respiratory multiple joint testing products have yet to obtain a domestic registration certificate. Overseas, there are CE certificates for single and multiple combined joint testing products such as COVID-19, influenza A and B, respiratory syncytial virus, adenovirus, etc.
Botuo Biotech (688767.SH): A total cost of 14.76 million yuan to buy back 0.42% of shares
Gelonghui, January 2, 丨 Botuo Biotech (688767.SH) announced that as of December 31, 2023, the company had repurchased 450,000 shares of the company's shares through centralized bidding transactions, accounting for 0.4219% of the company's total share capital of 106,666,667 shares. The highest price of the repurchase transaction was 33.48 yuan/share, the lowest price was 30.79 yuan/share, and the total amount of capital paid was RMB 14,760,652.50.
Botuo Biotech (688767.SH): First repurchase of 81,000 shares
Gelonghui (688767.SH) announced on December 14 | Botuo Biotech () announced that as of December 14, 2023, the company initially repurchased 81,047 shares of the company's shares through centralized bidding through the Shanghai Stock Exchange trading system, accounting for 0.076% of the company's total share capital of 106,666,667 shares. The maximum price of the repurchase transaction was 33.48 yuan/share, the lowest price was 33.15 yuan/share, and the total capital paid was RMB 2,699,220.20.
Analysis
Price Target
No Data
